Cancer Centers in the News

The following links highlight some of the most up-to-date news from the 27 NCCN Member Institutions. The media coverage below includes major national news outlets, industry magazines, medical journals, and press releases.

The news is listed in reverse chronological order for ease of use.

06/22/2017
Outpatient Clinics Take Up Residence in Shopping Malls (FierceHealthcare)
>View Article<



06/22/2017
Progression Free Survival with Nivolumab in Recurrent NSCLC (U.S. News and World Report)
>View Article<



06/22/2017
Cleveland Clinic Researchers Discover Similarities Between Next-Generation Prostate Cancer Drugs (Cleveland Clinic)
>View Article<



06/21/2017
Monitoring a Cancer Tumor is Sometimes Better Than Aggressive Treatment, Study Finds (HealthLine)
>View Article<



06/21/2017
First-Line Immunotherapy Treatment Can Improve Survival for Subset of Lung Cancer Patients (The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute)
>View Article<



06/21/2017
Huntsman Cancer Institute Unveils New Primary Children’s and Families’ Cancer Research Center (Utah Business)
>View Article<



06/21/2017
With a Rapper's Death, Harsh Spotlight Falls on Slow Progress against Sickle Cell (STAT)
>View Article<



06/21/2017
Many Doctors Silent on Cost of Cancer Care (HealthDay News)
>View Article<



06/20/2017
NCCN Guidelines Compliance for Chest CT Reduces False Positives and Decreases Health Care Spending in Breast Cancer, Study Finds

As published in JNCCN, a Siteman Cancer Center study uncovered potential to significantly improve NCCN Guidelines-concordant care in patients with early-stage breast cancer.

[FORT WASHINGTON, PA — June 20, 2017] According to SEER data, more than 260,000 women were diagnosed with breast cancer in the United States in 2016, most of whom were diagnosed with early-stage (stage I or II) disease. For this demographic, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) recommend standard imaging with bilateral mammography and ultrasound and, in some cases, breast MRI—the NCCN Guidelines® for Breast Cancer do not recommend chest computerized tomography (CT) scans in patients asymptomatic for distant metastases. Regardless, many asymptomatic patients undergo chest CT.

A recent study conducted by researchers at Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, led by Barbara Dull, MD, further confirmed the recommendations of the NCCN Guidelines panel. The study, “Overuse of Chest CT in Patients with Stage I and II Breast Cancer: An Opportunity to Increase Guidelines Compliance at an NCCN Member Institution,” is published in the June issue of JNCCN – Journal of the National Comprehensive Cancer Network.

Barbara Dull, MD

Using data from a prospective database, Dr. Dull and colleagues studied records of more than 3,300 patients diagnosed with early-stage breast cancer between 1998 and 2012 and found that 11% of patients with stage I and more than 36% of patients with stage II breast cancer underwent chest CT within six months of diagnosis, despite NCCN Guidelines recommendations. Of these 683 patients, only nine were diagnosed with pulmonary metastases. However, benign pulmonary nodules were discovered in 175 patients.

“The overwhelming majority of nodules found in this study’s patient population classified as false positive results,” said Dr. Dull. “Not only do the costs of the chest CT and subsequent imaging and work-up put a cost constraint on the already burdened health care system, but the psychological impact of such results on a patient and their family is enormous.”

 “I hope patients and their physicians are reassured by findings like these,” added Amy Cyr, MD, corresponding author of the study. “Chest CT and other staging studies are of extremely low yield for identifying metastases in patients with early-stage breast cancer, and even for the 1.3% of patients in our cohort ultimately diagnosed with pulmonary disease, many were not diagnosed because of that original CT scan, but were instead diagnosed on scans as long as two years after diagnosis, suggesting even lower utility. Unfortunately, for the 26.9% of patients with positive CT scans (the vast majority of which were false positives), the subsequent evaluation needed not only raises health care costs and anxiety, but also has the potential to delay oncologic treatment.”

Amy Cyr, MD

The NCCN Guidelines recommendations for patients with early-stage breast cancer are reinforced by other leading organizations in oncology, including the American Society of Clinical Oncology (ASCO), European Society for Medical Oncology (ESMO), and Britain’s National Institute for Health and Clinical Excellence (NICE).

According to the study, patients who underwent staging chest CT were generally younger and more likely to have unfavorable tumor markers. However, there were no statistical differences between patients diagnosed with metastases and those with false positive results.

“Even with numerous guidelines and recommendations, staging studies are routinely performed in patients with stage I and II breast cancer. Despite NCCN recommendations, many patients with asymptomatic early-stage breast cancer continue to undergo chest CT as part of their initial evaluation. Adherence to the NCCN Guidelines and other evidence-based recommendations will spare patients unnecessary testing and, in an era of increasing health care costs, also curb excessive spending,” said Dr. Dull.

The NCCN Guidelines are the recognized standard for clinical policy in cancer care and are often the most thorough and most frequently updated clinical practice guidelines available in any area of medicine.

“Notwithstanding the publicized potential risks of radiation exposure and the disputable value of chest CT in early-stage breast cancer, referring clinicians still order it, not infrequently, based on anecdotal cases, concerns regarding legal ramifications, or to satisfy insistent patients. At all stages of cancer care, including at presentation, during neoadjuvant or adjuvant therapy, and with advanced disease, evidence-based guidelines are needed to help direct treating physicians and their patients in selecting appropriate and indicated imaging studies,” said Pamela J. DiPiro, MD, Dana-Farber/Brigham and Women’s Cancer Center, in a June JNCCN commentary titled, “Evidence-Based Guidelines: Optimizing Imaging in Cancer Care.”

The study, “Overuse of Chest CT in Patients with Stage I and II Breast Cancer: An Opportunity to Increase Guidelines Compliance at an NCCN Member Institution,” is available free of charge until September 30, 2017 at JNCCN.org.

###

About JNCCN – Journal of the National Comprehensive Cancer Network
More than 24,000 oncologists and other cancer care professionals across the United States read JNCCN–Journal of the National Comprehensive Cancer Network. This peer-reviewed, indexed medical journal provides the latest information about best clinical practices, health services research, and translational medicine. JNCCN features updates on the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), review articles elaborating on guidelines recommendations, health services research, and case reports highlighting molecular insights in patient care. JNCCN is published by Harborside Press. Visit JNCCN.org. To inquire if you are eligible for a FREE subscription to JNCCN, visit http://www.nccn.org/jnccn/subscribe.asp

JNCCN 360 is a new online resource for oncology professionals featuring up-to-date news, literature, trials, clinical perspectives on current therapies, and much more. Visit JNCCN360.org

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.

>View Article<



06/20/2017
Proton Therapy is Now a Standard of Care Under Newest NCCN Guidelines (The University of Texas MD Anderson Cancer Center)
>View Article<



06/19/2017
Surgery and High-Dose SBRT Radiation Can Be Combined to Treat Kidney Cancer, Roswell Park Researchers Show (Roswell Park Cancer Institute)
>View Article<



06/01/2017
What’s Next? NCCN Gathers Health Care Policy Experts to Deliberate Challenges to Patient Safety and Access to Cancer Care under the New Administration

[FORT WASHINGTON, PA —June 1, 2017] Patient safety has long been recognized as an integral component of high-quality and effective medical care. The stakes are especially high in oncology, where avoiding errors is imperative to delivering safe and effective radiation therapy, chemotherapy, and other high-risk treatments. Moreover, there is uncertainty surrounding shifting health care priorities under the Trump administration and subsequent implications for safety and access to high-quality patient-centered cancer care.

During the National Comprehensive Cancer Network® (NCCN®) Policy Summit: Ensuring Patient Access and Safety in Cancer Care, experts will consider these and other pertinent issues, including changing paradigms in cancer treatment, access to clinical trials and “Right to Try” legislation, and patient safety and access issues within the overall context of an increasing focus on defining and delivering high-quality cancer care through payment models based on value rather than volume. The summit takes place on Thursday, June 15, 2017, from 9:30 am – 3:00 pm at the National Press Club in Washington, DC. For press credentials, contact NCCN Communications Manager Katie Kiley Brown at brown@nccn.org.

“Addressing safety issues throughout the cancer care continuum must be met with an increased focus on guidelines, awareness, resources, and training,” said F. Marc Stewart, MD, Oncologist and Medical Director, Seattle Cancer Care Alliance, and Co-Chair of the NCCN Best Practices Committee. “Understanding patient safety issues from patient, provider, and cancer center perspectives and recognizing the innovative approaches to address these gaps are integral components of high-quality cancer care.”

Clifford Goodman, PhD, of The Lewin Group will moderate the summit, which will consist of short presentations followed by roundtable discussions with lively discourse and ample time for audience questions. An abbreviated agenda is below.

As developers of the widely used NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) that set the standard of cancer care in the United States, NCCN is invested in provision of high-quality, safe, value-based cancer care. Moreover, the library of NCCN Chemotherapy Order Templates (NCCN Templates®) include chemotherapy, immunotherapy, supportive care agents, monitoring parameters, and safety instructions based directly on recommendations within the NCCN Guidelines®. The NCCN Templates® were initially published as a result of the first NCCN patient safety policy summit held in 2006, and today NCCN has published more than 1,500 chemotherapy order templates, which have been integrated into various electronic health record (EHR) platforms for use at point of care.

AGENDA*

Welcome and Introductions

Robert W. Carlson, MD, National Comprehensive Cancer Network

 

Safety and Accountability in Oncology Care

F. Marc Stewart, MD, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

 

Panel Discussion:

Safety and Accountability in Cancer Care; Past, Present, and Future

Moderated by Clifford Goodman, PhD, The Lewin Group

Panelists:

Amy P. Abernethy, MD, PhD, Flatiron

Jonathan S. Deutsch, MD, Bristol-Myers Squibb

Terry Langbaum, MHS, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Steven R. Peskin, MD, MBA, FACP, Horizon Blue Cross Blue Shield of New Jersey

F. Marc Stewart, MD, Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance

 

Patient Access to Safe, High-Quality Cancer Care under a New Administration

Clifford A. Hudis, MD, FACP, FASCO, American Society of Clinical Oncology (ASCO)


Panel Discussion:

Barriers and Opportunities in Ensuring Access to Safe, High-Quality Cancer Care

Moderated by Clifford Goodman, PhD, The Lewin Group

Panelists:

Eliot Fishman, PhD, Families USA

Bruce Gould, MD, Northwest Georgia Oncology Centers

Clifford A. Hudis, MD, FACP, FASCO, ASCO

Lee Newcomer, MD, MHA, UnitedHealthcare 

Caroline Pearson, Avalere

Rodney L. Whitlock, PhD, ML Strategies

*Subject to change.

For more information about the NCCN Oncology Policy Program and to register for the event, visit NCCN.org/policy.

###

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.

>View Article<



05/25/2017
NCCN Awards Grants to Investigators at Member Institutions to Study Osimertinib in Lung Cancer

These studies were funded through a collaboration with AstraZeneca to evaluate the effectiveness of osimertinib in EGFRm+ non-small cell lung cancer

[FORT WASHINGTON, PA — May 25, 2017] The National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) has funded two investigators from NCCN Member Institutions through a collaborative scientific research relationship with AstraZeneca to further evaluate the clinical effectiveness of osimertinib in the treatment of epidermal growth factor receptor-positive (EGFRm+) non-small cell lung cancer (NSCLC).

The following studies were awarded funding through NCCN ORP:

“NCCN ORP congratulates Dr. Gomez and Dr. Jänne on their awards and looks forward to the commencement of their studies,” said Susan Most, RN, MBA, Director, Clinical Operations, NCCN ORP. “We are pleased to be working with AstraZeneca on further evaluation of osimertinib, an important targeted agent for the treatment of EGFRm+ non-small cell lung cancer. This project furthers NCCN’s commitment to improving the lives of patients with cancer by providing opportunities to identify additional treatment options in lung cancer.”

Submissions were peer reviewed by the NCCN Osimertinib Scientific Review Committee. The funded concepts were selected based on several criteria, including scientific merit, existing data, and the types of studies necessary to further evaluate the efficacy of osimertinib.

NCCN ORP draws upon the expertise of investigators at the NCCN Member Institutions and their affiliates to facilitate all phases of clinical research. This research is made possible by collaborations with pharmaceutical and biotechnology companies in order to advance therapeutic options for patients with cancer. To date, this successful research model has received more than $60 million in research grants and supported more than 140 studies, producing a number of publications in peer-reviewed journals.

To learn more about the NCCN ORP and ongoing clinical trials, visit NCCN.org/ORP.

###

About the National Comprehensive Cancer Network
The National Comprehensive Cancer Network® (NCCN®), a not-for-profit alliance of 27 leading cancer centers devoted to patient care, research, and education, is dedicated to improving the quality, effectiveness, and efficiency of cancer care so that patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. As the arbiter of high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers.

The NCCN Member Institutions are: Fred & Pamela Buffett Cancer Center, Omaha, NE; Case Comprehensive Cancer Center/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute, Cleveland, OH; City of Hope Comprehensive Cancer Center, Los Angeles, CA; Dana-Farber/Brigham and Women’s Cancer Center | Massachusetts General Hospital Cancer Center, Boston, MA; Duke Cancer Institute, Durham, NC; Fox Chase Cancer Center, Philadelphia, PA; Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT; Fred Hutchinson Cancer Research Center/Seattle Cancer Care Alliance, Seattle, WA; The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL; Mayo Clinic Cancer Center, Phoenix/Scottsdale, AZ, Jacksonville, FL, and Rochester, MN; Memorial Sloan Kettering Cancer Center, New York, NY; Moffitt Cancer Center, Tampa, FL; The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute, Columbus, OH; Roswell Park Cancer Institute, Buffalo, NY; Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine, St. Louis, MO; St. Jude Children’s Research Hospital/The University of Tennessee Health Science Center, Memphis, TN; Stanford Cancer Institute, Stanford, CA; University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL; UC San Diego Moores Cancer Center, La Jolla, CA; UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA; University of Colorado Cancer Center, Aurora, CO; University of Michigan Comprehensive Cancer Center, Ann Arbor, MI; The University of Texas MD Anderson Cancer Center, Houston, TX; University of Wisconsin Carbone Cancer Center, Madison, WI; Vanderbilt-Ingram Cancer Center, Nashville, TN; and Yale Cancer Center/Smilow Cancer Hospital, New Haven, CT.

Clinicians, visit NCCN.org. Patients and caregivers, visit NCCN.org/patients. Media, visit NCCN.org/news.

>View Article<



05/19/2017
NCCN and Pfizer Address Quality Improvement in Breast Cancer through Clinical Pathways

NCCN and Pfizer seek grant proposals for use of clinical care pathways aimed at quality improvement along the continuum of care for patients with breast cancer.

[FORT WASHINGTON, PA — May 19, 2017] Evidence- and systems-based standardization of clinical processes, such as the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), support decision-making and quality improvement in the care of patients with cancer. Moreover, clinical pathways have emerged as point-of-care informational tools used by health care providers to improve quality of care based on the most current medical evidence and recommendations within the NCCN Guidelines®.

To further encourage and subsequently evaluate such programs, the National Comprehensive Cancer Network® (NCCN®) Oncology Research Program (ORP) is working with Pfizer Independent Grants for Learning & Change (IGLC) to fund grant proposals for projects utilizing clinical care pathways to address a quality improvement (QI) initiative along the continuum of care for patients with breast cancer.

The Request for Proposals (RFP) issued by NCCN and Pfizer strongly encourages proposals that address the use of clinical pathways in community centers, low-resource centers, and centers that focus on the treatment of underserved patients with cancer. All U.S.-based organizations, including NCCN Member Institutions, community affiliates of NCCN Member Institutions and other academic medical centers, and community cancer centers are encouraged to submit proposals.

“NCCN recognizes the emerging role of evidence-based clinical care pathways in cancer, and we are pleased to once again align with Pfizer IGLC to improve the quality of care of people with breast cancer, particularly those in underserved communities across the United States,” said Susan Most, RN, MBA Director, Clinical Operations, NCCN ORP.

The RFP seeks proposals in two specific areas of interest:

  • Clinical Care Pathways Development
    • Develop and implement programs that improve efficiency and reduce costs to improve the quality of breast cancer patient care, including one or more of the following:
      • May be technology based, but it is not necessary
      • Support multidisciplinary collaboration
      • Include partnerships to improve access to multidisciplinary and specialized care
      • Improve patient adherence to medications and improve patient safety
      • Address patient emotional needs, psychosocial support and advocacy issues
      • May incorporate virtual tumor boards, telemedicine, support services etc.
      • May reduce payers’ administrative burden for authorization or provers’ burden for payment of care for patients with breast cancer
  • Clinical Care Pathways Implementation or Education
    • Demonstration of care or process improvement in centers through the utilization of pathway programs
    • Integration into electronic health records
    • Implementation throughout healthcare system/affiliates
    • Strategies for provider training and education

The NCCN ORP, organized to obtain funding to support scientifically meritorious research studies at NCCN Member Institutions and other centers, leads the organization for review and evaluation of applications. A review committee, led by NCCN and including a medical representative from Pfizer, will decide which proposals will receive funding. Grant funding will be provided by Pfizer IGLC.

The RFP deadline is June 26, 2017. For more information about NCCN ORP and view the RFP, visit NCCN.org/ORP.

###
 

>View Article<



05/03/2017
Half of Breast Cancer Patients Pursue Reconstructive Surgery without Understanding of Risks (The Ohio State University Comprehensive Cancer Center – James Cancer Hospital and Solove Research Institute)
>View Article<



05/03/2017
Breakthrough Study Stops Fat-Eating Prostate Cancer Cells (University of Colorado Cancer Center)
>View Article<



05/03/2017
Mini-IV Drip Bag Delivery of Vincristine Avoids Risk of Deadly Errors (CancerNetwork)
>View Article<



05/03/2017
Cancer-Causing Virus Masters Cell’s Replication and Immortality (Duke Cancer Institute)
>View Article<



05/03/2017
Multimodal Strategy Shows Promise in Metastatic Prostate Cancer (Oncology Nurse Advisor)
>View Article<



05/01/2017
Global Cancer Program Harnesses UCSF's Expertise to Take on Cancer (UCSF Helen Diller Family Comprehensive Cancer Center)
>View Article<